Huang Hui, Xiang Jim
Research Unit, Saskatchewan Cancer Agency, Department of Microbiology, University of Saskatchewan, Saskatoon, Canada.
Int J Cancer. 2004 May 10;109(6):817-25. doi: 10.1002/ijc.20043.
The lack of efficient T-cell infiltration of tumors is a major obstacle to successful adoptive T-cell therapy. We have previously demonstrated that adenovirus (AdV)-mediated transgene lymphotactin (Lptn) or IP-10 expression in tumors can significantly enhance T-cell tumor infiltration. In this study, active OVA-specific CD8+ T cells were prepared by coculturing naive OVA-specific CD8+ T cells from transgenic OT I mice with OVA-I peptide-pulsed dendritic cells in vitro. These XCR-1- and CXCR3-expressing T cells predominantly secreted IFN-gamma and displayed significant killing activity (84% at effector:target cell ratio of 1.5) against OVA-expressing EG7 tumor cells through perforin-mediated pathway. Our data also showed that chemokine Lptn and IP-10 not only can chemoattract, but also stimulate proliferation of CD8+ T cells in vitro, and that a mixture of Lptn and IP-10 can more efficiently chemoattract CD8+ T cells than either one of them. Furthermore, we demonstrated that the transferred CD8+ T cells detected in group of tumors treated with both AdVLptn and AdVIP-10 (group a) are around 4 and 2 times more than that in groups of tumors treated with control AdVpLpA (group b) and either AdVIP-10 (group c) or AdVLptn (group d), respectively. Around 87.5% of mice in group a were tumor-free compared to the aggressive tumor growth in all 8 mice of group b and 25% or 37.5% cured mice seen in groups c and d (p<0.05). Thus, our results indicate that enhancement of adoptive T-cell therapy can be obtained by double tranmsgene Lptn and IP-10 expression, which facilitates CD8+ T-cell tumor localization through proliferation and chemoattraction of the transferred CD8+ T cells by in situ chemokine transgene expressions in the tumors. Collectively, our data provide solid evidence of a potent synergy between adoptive T-cell therapy and adenovirus-mediated Lptn and IP-10 gene transfer into tumor tissues, which culminated in the T-cell tumor localization and eradication of well-established tumor masses.
肿瘤缺乏有效的T细胞浸润是过继性T细胞治疗成功的主要障碍。我们之前已经证明,腺病毒(AdV)介导的肿瘤中转基因lymphotactin(Lptn)或IP-10表达可显著增强T细胞的肿瘤浸润。在本研究中,通过在体外将来自转基因OT I小鼠的初始OVA特异性CD8 + T细胞与OVA-I肽脉冲树突状细胞共培养,制备了活性OVA特异性CD8 + T细胞。这些表达XCR-1和CXCR3的T细胞主要分泌IFN-γ,并通过穿孔素介导的途径对表达OVA的EG7肿瘤细胞表现出显著的杀伤活性(效应细胞:靶细胞比例为1.5时为84%)。我们的数据还表明,趋化因子Lptn和IP-10不仅可以趋化,还能在体外刺激CD8 + T细胞增殖,并且Lptn和IP-10的混合物比它们中的任何一种都能更有效地趋化CD8 + T细胞。此外,我们证明,在同时用AdVLptn和AdVIP-10治疗的肿瘤组(a组)中检测到的转移CD8 + T细胞分别比用对照AdVpLpA治疗的肿瘤组(b组)以及用AdVIP-10(c组)或AdVLptn(d组)治疗的肿瘤组中的转移CD8 + T细胞多约4倍和2倍。a组中约87.5%的小鼠无肿瘤,而b组的所有8只小鼠肿瘤生长侵袭性强,c组和d组的治愈小鼠分别为25%或37.5%(p<0.05)。因此,我们的结果表明,通过双转基因Lptn和IP-10表达可以增强过继性T细胞治疗,这通过肿瘤中趋化因子转基因原位表达促进转移的CD8 + T细胞增殖和趋化,从而促进CD8 + T细胞在肿瘤中的定位。总体而言,我们的数据为过继性T细胞治疗与腺病毒介导的Lptn和IP-10基因转移到肿瘤组织之间的强大协同作用提供了确凿证据,这最终导致T细胞在肿瘤中的定位以及根除已形成的肿瘤块。